mardi 23 juin 2020

Onco Actu du 23 juin 2020

U.S. court blocks California cancer label on Bayer's Roundup weed killer [Reuters] 
In his ruling, U.S. District Judge William Shubb called California’s cancer warning misleading and said the state’s label is not backed up by regulatory findings.

Biomarker Test Highly Accurate in Detecting Early Kidney Cancer [Dana-Farber Cancer Institute] 
The technical name for the testing method is cfMeDIP-seq, which stands for cell-free methylated DNA immunoprecipitation and high-throughput sequencing.

Boulder, CO-based ArcherDx develops lab tests intended to guide cancer treatment decisions. The Stratafide product is a lab test and companion diagnostic that analyzes DNA, RNA, and circulating tumor DNA from either a blood or tissue sample.

Single-Cell Analysis of Ovarian Cancer Points to Potential Treatment Avenue [Genome Web] 
As they reported in Nature Medicine on Monday, the researchers further found that an inhibitor targeting the JAK/STAT pathway, which is expressed in both malignant and cancer-associated fibroblast cells (CAFs), had antitumor activity in cell cultures and patient-derived xenografts.

New class of precision medicine strips cancer of its DNA defences [Institute of Cancer Research] 
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, led a trial of the benefit of an ATR inhibitor called berzosertib either on its own or with chemotherapy in 40 patients with very advanced tumours, treated in hospitals around the world.

Cancer drug: New treatment halts tumour growth [BBC News] 
“The unusually strong effects of berzosertib, especially in combination with conventional chemotherapy, give reasons to be optimistic regarding the outcomes of follow-up studies."

EMA to consider expanding use of Merck/Pfizer's Bavencio [Pharma Times] 
The European Medicines Agency has validated for review Merck and Pfizer's application to market Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10) [Merck] 
KEYTRUDA Is Now Approved Across Five indications for Three Different Types of Cancer in China and Is First Anti-PD-1 Therapy Approved for Esophageal Cancer.

Immune Cells Infiltrating Tumors May Play Bigger Cancer Role Than Previously Thought [UCSD] 
The study, published in PLoS Biology, is the first to uncover the role a molecule called IRE1α plays in determining whether macrophages promote inflammation in the tissues surrounding cancer cells — a region known as the tumor microenvironment — and throw off the ability of other immune cells to fight cancer. 

Study led by TGen and City of Hope shows new way of identifying tumor response to immunotherapy [TGen] 
The findings highlight, for the first time, an important predator-prey relationship between circulating immune cell dynamics and a tumor’s response to immunotherapy. 

Jazz preps first solid tumor launch with Zepzelca's small cell lung cancer nod [Fierce Pharma] 
The Zepzelca launch is physician-focused to make sure doctors are aware that the drug exists, Jazz Chairman and CEO Bruce Cozadd said. About 30,000 people in the U.S. are diagnosed with small cell lung cancer every year, and about 17,000 of them go on to second-line treatment.

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma [FDA] 
Approval was based on SADAL (KCP-330-009; NCT02227251), a multicenter, single-arm, open-label trial in patients with DLBCL after 2 to 5 systemic regimens. 

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Karyopharm] 
XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL.

FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma [ESMO] 
FDA also approved the cobas EZH2 Mutation Test as a companion diagnostic for tazemetostat.

What's the hard cost of a pivotal drug trial? A lot less than you might expect [EndPoints] 
After plugging details about 101 new drugs approved between 2015 and 2017 into a clinical trial cost estimator created by IQVIA, the authors concluded that the estimated median pivotal trial cost was $48 million, with an interquartile range of $20 million to $102 million.

AACR Virtual Annual Meeting II: Opening Ceremony Sets Focus on Science, Policy [AACR] 
The Opening Ceremony of the American Association for Cancer Research (AACR) Virtual Annual Meeting II provided a stark reminder that while the entire world takes aim at the COVID-19 pandemic, cancer remains a relentless foe, requiring a resolute focus of its own. 

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset [EndPoints] 
Among the 24 patients signed up for the Phase Ia study using escalating doses of tiragolumab, none demonstrated an objective response to the monotherapy, according to the abstract posted by AACR.

AACR 2020 – Biontech and Roche try to resuscitate cancer vaccines [EndPoints] 
A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history.

AACR Virtual Annual Meeting 2020 II: MSK Research Shows that Young Adults with Early-Onset Cancer Are at High Risk of Harboring Inherited Genetic Mutations [Memorial Sloan Kettering Cancer Center] 
Among patients with early-onset cancers, the highest rates of genetic mutations were found in those with cancer in the pancreas, breast, or kidney, with mutations in the BRCA1, BRCA2, ATM, CHEK2, and the Lynch syndrome-associated genes being the most frequent.

TGen’s Ashion Analytics® and HonorHealth show how ‘organoids’ can help pinpoint the right therapies for cancer patients [TGen] 
PATRIOT, which stands for PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics, will be showcased in a study presentation June 22-24 at the second 2020 virtual annual meeting of the American Association for Cancer Research (AACR).

GRAIL to Present New Data Supporting its Multi-Cancer Early Detection Test at the American Association for Cancer Research (AACR) Annual Meeting II [GRAIL] 
GRAIL’s multi-cancer early detection test is supported by evidence from its population-scale clinical study program, which is believed to be the largest ever conducted in genomic medicine.

Getting cancer services back on track during the COVID-19 pandemic [Cancer Research UK] 
Here’s what we think needs to happen to make sure patients get the care they need, when they need it.